Finance

RNAi company reports reduced losses in Q3

Published in Obesity and Diabetes Week, December 13th, 2004

CytRx Corp. (CYTR) reported its consolidated financial results for the quarter ended September 30, 2004.

CytRx Corp. (CytRx), a small-molecule drug-development and RNA interference (RNAi) technology company, is focused on creating a significant and sustainable product line to modify proteins responsible for ALS (amyotrophic lateral sclerosis), obesity, type 2 diabetes, HIV, and cytomegalovirus.

Steven Kriegsman, CytRx's president and CEO, stated, "In the third quarter of 2004, we were very pleased to have been able to reduce our losses from the previous quarter. We also negotiated the acquisition of the clinical and pharmaceutical assets of Biorex...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2004-12-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry